You are here
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: Flow Pharma, Inc. Topic: CBD18A002
Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: Luna Innovations Incorporated Topic: CBD18A002
Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense